Burning Rock Biotech (BNR) Gross Profit (2019 - 2026)

Burning Rock Biotech (BNR) has reported Gross Profit for 8 consecutive years, with $11.3 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Gross Profit fell 15.74% year-over-year to $11.3 million; the TTM figure through Mar 2026 stood at $54.4 million (up 4.79% YoY), while the FY2025 annual figure was $57.6 million, up 16.05% from the prior year.
• Gross Profit came in at $11.3 million for Q1 2026 at Burning Rock Biotech, down from $14.1 million in the prior quarter.
• The five-year high for Gross Profit was $15.3 million in Q3 2022, with the low at $11.0 million in Q4 2023.
• Average Gross Profit over 5 years is $13.2 million, with a median of $13.4 million recorded in 2025.
• Across the five-year window, Gross Profit advanced 17.64% in 2022 and decreased 25.06% in 2023, its largest moves.
• Year by year, Gross Profit stood at $14.7 million in 2022, then fell by 25.06% to $11.0 million in 2023, then rose by 11.35% to $12.3 million in 2024, then gained by 15.05% to $14.1 million in 2025, then retreated by 19.76% to $11.3 million in 2026.
• According to Business Quant data, Gross Profit over the past three periods registered $11.3 million, $14.1 million, and $13.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.